Evidence map›Paper›PMID 40331953›Full record

ArticleInternational journal of molecular sciences2025

High Mobility Group Box 1 Is Potential Target Therapy for Inhibiting Metastasis and Enhancing Drug Sensitivity of Hepatocellular Carcinoma.

Arunya Jiraviriyakul, Chatchai Nensat, Samitanan Promchai, Yanisa Chaiaun, Yanisa Hoiraya, Nutnicha Yamnak, Suphakit Khutanthong, Nun Singpan, Worawat Songjang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Arunya JiraviriyakulIntegrative Biomedical Research Unit (IBRU), Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand.ORCID 0000-0003-0122-5984
Chatchai NensatIntegrative Biomedical Research Unit (IBRU), Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand.
Samitanan PromchaiBiomedical Sciences Program, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand.
Yanisa ChaiaunMedical Technology Program, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand.
Yanisa HoirayaMedical Technology Program, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand.
Nutnicha YamnakMedical Technology Program, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand.
Suphakit KhutanthongDepartment of Pathology, Faculty of Medicine, Naresuan University, Phitsanulok 65000, Thailand.ORCID 0000-0001-7635-9421
Nun SingpanDepartment of Pathology, Faculty of Medicine, Naresuan University, Phitsanulok 65000, Thailand.
Worawat SongjangIntegrative Biomedical Research Unit (IBRU), Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand.

Funding

Naresuan University (NU), and National Science, Research and Innovation Fund (NSRF) R2566B083University Income Fund, Naresuan University R2567C026
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a lethal malignancy associated with drug resistance, resulting in a poor prognosis. High mobility group box 1 (HMGB1) is a chromatin-binding protein that regulates HCC progression. The overexpression of HMGB1 has been found to promote tumorigenesis and drug resistance. In this study, we aimed to investigate the role of HMGB1 expression in tumorigenesis and metastasis and its impact on sorafenib and oxaliplatin resistance. Tissue samples from patients with HCC (

Indexed as

Carcinoma, HepatocellularDrug Resistance, NeoplasmHMGB1 ProteinLiver NeoplasmsAgedAntineoplastic AgentsCell AdhesionCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm MetastasisAntineoplastic AgentsHMGB1 ProteinHMGB1 protein, humanOxaliplatinSorafenibhepatocellular carcinoma (HCC)high mobility group box 1 (HMGB1)metastasisoxaliplatinsorafenib

Identifiers

PMID40331953
PMCPMC12026555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.